1. Nazrun AS, Tzar MN, Mokhtar SA, Mohamed IN. A systematic review of the outcomes of osteoporotic fracture patients after hospital discharge: morbidity, subsequent fractures, and mortality. Ther Clin Risk Manag, 2014, 10: 937–948.
2. Chinese Medical Association of Osteoporosis and Bone Mineral Disease. Guidelines for the diagnosis and treatment of primary osteoporosis (2017). Zhongguo Shiyong Neike Zazhi, 2018, 38(2): 127–150.
3. Zhang Q, Zhu C. Metrology and visual analysis of English literature regarding osteoporosis in the past 5 years: based on the Web of Science. Zhongguo Zuzhi Gongcheng Yanjiu, 2020, 24(17): 2752–2758.
4. Si L, Winzenberg TM, Jiang Q, Chen M, Palmer AJ. Projection of osteoporosis-related fractures and costs in China: 2010–2050. Osteoporos Int, 2015, 26(7): 1929–1937.
5. Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C. Efficacy and safety of recombinant human parathyroid hormone (1–34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis. Medicine (Baltimore), 2018, 97(47): e13341.